Stentys Begins Precommercialization of Serpentis SES in Europe


November 13, 2017—Stentys announced the precommercialization of Serpentis, its new sirolimus-eluting stent, which is composed of a thin cobalt chromium mesh with a bioabsorbable polymer coating for routine procedures. Codeveloped with a French industrial partner, Serpentis has received European CE Mark approval and will be available by the end of the year to a selection of pilot centers across Europe.

Stentys' Serpentis is dedicated to routine procedures, whereas the company's Xposition S device is designed for more complex indications.

The company advised that the efficacy of the Xposition S was demonstrated in interim results from the SIZING study, which were presented at TCT 2017, the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium held October 30 to November 2 in Denver, Colorado.

The SIZING international registry enrolled 1,300 patients to conduct a large-scale assessment of Xposition S in clinical practice. The results of the analysis of the cohort treated with Xposition S (588 patients) validated the benefits of using this self-apposing stent for complex anatomies.

In 36% of cases, Xposition S was selected for lesions on vessels of varying diameters, in 17% of cases for thrombotic lesions, in 16% of cases for bifurcations, in 7.5% of cases for vein grafts, and in 27% of analyzed cases presented a substantial vessel diameter (≥ 4.5 mm).

Stentys reported that despite these complex anatomies, a low rate of major adverse cardiac events was observed after 12 months of monitoring, as well as a low rate of stent thrombosis (0.75%). The results of this exploratory analysis of the SIZING data confirm the benefits of self-apposing coronary stents in the treatment of specific lesions, leading to a low major adverse cardiac event rate, stated the company.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.